Glaukos

GKOS

Market cap $6.1B

GKOS gains momentum from iDose TR's strong launch and a growing pipeline, though reimbursement hurdles pose challenges ahead.

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Glaukos Corporation ( GKOS ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Alex Thurman - Senior VP & CFO Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Good morning, everyone. Thank you so much for joining.

Baltimore-based Brown Capital Management sold 376,359 shares of Glaukos Corporation for an estimated $34.6 million in the third quarter. The transaction value equaled approximately 1.4% of fund's 13F assets under management at quarter-end.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 11, 2025, at 10:15 a.m. ET in Palm Beach, FL Stifel Healthcare Conference on Wednesday, November 12, 20.

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products.

Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.

Glaukos Corporation ( GKOS ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Christopher Lewis - Vice President of Investor Relations & Corporate Affairs Thomas Burns - Chairman & CEO Joseph Gilliam - President & COO Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Adam Maeder - Piper Sandler & Co., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division K. Gong - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Richard Newitter - Truist Securities, Inc., Research Division Mason Carrico - Stephens Inc., Research Division David Saxon - Needham & Company, LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Michael Sarcone - Jefferies LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.

Glaukos (GKOS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.28 per share a year ago.